Novo Nordisk is trading 3.1% up at $51.19 as shares benefit from a broader healthcare sector rally and a rotation away from technology stocks.
- The stock is rebounding further after recent weakness, gaining momentum as investors favor defensive healthcare names.
- With no fresh headlines or earnings on July 28, 2026, the advance is primarily tied to a shift from AI-exposed stocks into blue-chip value plays.